Pricing and Contracting Strategy for a Biosimilar Launch

2020-02-18T15:41:03+00:00Case Studies|

A large manufacturer client was preparing to launch a biosimilar into a highly competitive and complex market. In this case study, the brand team sought to learn how payers would view the product in relation to key competitors, understand decision drivers and thresholds, and identify potential competitive reactions resulting from any actions taken.

How FDAMA Section 114 Helps Pharma Inform Payers

2020-02-18T15:41:04+00:00Case Studies|

Section 114 of the Food and Drug Administration Modernization Act of 1997 (FDAMA) was designed to allow pharmaceutical manufacturers to share health economic information with payers. This study shows how, by working in partnership with a pharmaceutical manufacturer, our scientists assessed COPD-related outcomes based on administrative claims data among combination therapy–naive patients—and enabled the client to engage payers on the benefits of its treatment.

A Structured Approach to Inform a Preliminary Pricing Strategy

2020-02-18T15:41:17+00:00Case Studies|

A biotech company was preparing to launch a new PET imaging agent for prostate cancer patients with suspected biochemical recurrence into the US market. While a high unmet need continued to exist in recurrent prostate cancer, challenges remained in communicating the value of—and gaining reimbursement for—radiochemical imaging agents. This case study shares the approach to a well-structured preliminary pricing strategy to mitigate these challenges and drive success for the product.

Global Stakeholder Insights-Gathering Informs Optimal Biosimilar Pricing Strategies

2020-02-18T15:41:27+00:00Case Studies|

A pharmaceutical manufacturer was preparing to launch 2 biosimilars with autoimmune disease indications across 6 European markets. With several access challenges for both products anticipated, this case study shares our approach to the assessment of likely access conditions and price potentials at launch, as well as the evidence generation needed to improve those scenarios across markets. The findings were critical to informing the development of a pricing strategy for both biosimilars.

Improving Payer Engagements Around Smoking Cessation

2020-02-18T15:41:35+00:00Case Studies|

Three HEDIS measures had been issued by the National Committee for Quality Assurance regarding payer performance on smoking cessation among members.
Despite this, payers had a limited understanding of how smoking cessation quality measures were impacting their overall rating vs other regional health or national benchmarks. This study shows how specific smoking cessation support services were promoted to gain improvement in payer coverage for the products while adhering to PhRMA guidelines.

An Incorrect Quantity Limit Leads to a Tactical Plan That Targets PBMs and Plans

2020-02-18T15:41:35+00:00Case Studies|

A leading pharmaceutical manufacturer had recently obtained an indication for once daily use (OaD) for erectile dysfunction to supplement its original “as needed (PRN)” indication. With quantity limits (QLs) of 4 to 8 tablets existing on its and similar PRN products, a spillover effect resulted in an accidental blanket QL placed on the drug, even when appropriately prescribed for OaD use. Discover how Precision helped get the QLs reversed.